Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms

International Journal of Hematology

Volumn 100, Issue 5, 2014, Pages 429-436

  Kissova, Jarmila ^a   Bulikova, Alena ^a   Ovesna, Petra ^b   Bourkova, Ludmila ^a   Penka, Miroslav ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

BCR ABL negative myeloproliferative neoplasms (MPN); Immature platelet fraction (IPF); Mean platelet volume (MPV); Thrombosis

Indexed keywords

BCR ABL PROTEIN; ANAGRELIDE; ANTITHROMBOCYTIC AGENT; JANUS KINASE 2; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BLOOD CELL COUNT; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; IMMATURE PLATELET FRACTION; MAJOR CLINICAL STUDY; MALE; MYELOPROLIFERATIVE NEOPLASM; RISK ASSESSMENT; THROMBOCYTE VOLUME; VEIN THROMBOSIS; BLOOD; CASE CONTROL STUDY; COMPLICATION; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; PATHOLOGY; RISK FACTOR; THROMBOCYTE; THROMBOSIS;

ADULT; AGED; BLOOD PLATELETS; CASE-CONTROL STUDIES; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; JANUS KINASE 2; MALE; MEAN PLATELET VOLUME; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; PLATELET AGGREGATION INHIBITORS; QUINAZOLINES; RISK FACTORS; THROMBOSIS;

EID: 84919922418     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-014-1673-0     Document Type: Article

References (39)

1. Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, Mazzucconi MG, Rodeghiero F, Tura S. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004;89:215–32.
2. Tefferi A, Murphy S. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. Blood Rev. 2001;15:121–31.
3. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusamolino E, Pascutto C, Cazzola M, Morra E, Lazzarino M. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117:755–61.
4. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:2224–32.
5. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, Van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR. United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33–45.
6. Elliot MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128:275–90.
7. Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M, Manarini S, Finazzi G, Cerletti C, Barbui T. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000;96:4261–6.
8. Arellano RE, Alvarez LA, Reverter JC, Colomer D, Villamor N, Bellosillo B, Cervantes F. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol. 2009;84:102–8.
9. Falanga A, Russo L, Marchetti M. Mechanisms of thrombogenesis. In: Barbui T, Tefferi A, editors. Myeloproliferative neoplasms. Springer- Verlag: Berlin Heidelberg; 2012. p. 57–67.
10. Harrison CN (2005) Platelets and thrombosis in myeloproliferative diseases. Hematology Am Soc Hematol Educ Program 409–15.
11. Michiels JJ, Berneman Z, Van Bockstaele D, Van der Planken M, De RH, Schroyens W. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost. 2006;32:174–207.
12. Arellano RE, Alvarez LA, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006;91:169–75.
13. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol. 2005;33:523–30.
14. Jensen MK, Nully BP, Lund BV, Nielsen OJ, Hasselbach HC. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol. 2000;110:116–24.
15. Kamath S, Blann AD, Lip GY. Platelet activation: assessment and quantification. Eur Heart J. 2001;22:1561–71.
16. Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis. 1996;7:157–61.
17. Slavka G, Perkmann T, Haslacher H, Greisenegger S, Marsik C, Wagner OF, Endler G. Mean platelet volume may represent a predictive parameter for overall vascular mortality and ischemic heart disease. Arterioscler Thromb Vasc Biol. 2001;31:1215–8.
18. Berger JS, Eraso LH, Xie D, Sha D, Mohler ER. Mean platelet volume and prevalence of peripheral artery disease, the National Health and Nutrition Examination Survey, 1999-2004. Atherosclerosis. 2010;213:586–91.
19. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, Mohler ER, Reilly MP, Berger JS. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. Thromb Heamost. 2010;8:148–56.
20. Endler G, Klimesch A, Sunder PH, Schillinger M, Exner M, Mannhalter C, Jordanova N, Christ G, Thalhammer R, Huber K, Sunder PR. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol. 2002;117:399–404.
21. Bath P, Algert C, Chapman N, Neal B. Progress Collaborative Group: association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke. 2004;5:622–6.
22. Braekkan SK, Mathiesen EB, Njølstad I, Wilsgaard T, Størmer J, Hansen JB. Mean platelet volume is a risk factor for venous thromboembolism: the Tromsø Study, Tromsø, Norway. J Thromb Haemost. 2010;8:157–62.
23. Ingram M, Coopersmith A. Reticulated platelets following acute blood loss. Br J Haematol. 1969;7:225–9.
24. Cesari F, Marcucci R, Caporale R, Paniccia R, Romano E, Gensini GF, Abbate R, Gori AM. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost. 2008;99:930–5.
25. Cesari F, Marcucci R, Gori AM, Caporale R, Fanelli A, Casola G, Balzi D, Barchielli A, Valente S, Giglioli C, Gensini GF, Abbate R. Reticulated platelets predict cardiovascular death in acute coronary syndrome patients. Insights from the AMI-Florence 2 Study. Thromb Haemost. 2013;109:846–53.
26. Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost. 2009;101:151–6.
27. Nakamura T, Uchiyama S, Yamazaki M, Okubo K, Takakuwa Y, Iwata M. Flow cytometric analysis of reticulated platelets in patients with ischemic stroke. Thromb Res. 2002;106:171–7.
28. Würtz M, Grove EL, Wulff LN, Kaltoft AK, Tilsted HH, Jensen LO, Hvas AM, Kristensen SD. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. JACC Cardiovasc Interv. 2010;3:828–35.
29. Biggs C, Kunka S, Hart D, Oguni S, Machin SJ. Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia. Br J Haematol. 2004;126:93–9.
30. Falanga A, Marchetti M (2012) Thrombotic disease in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program p. 571–81.
31. Diquattro M, Gagliano F, Calabró GM, Tammasi M, Scott CS, Mancuso G, Palma B, Menozzi I. Relationships between platelet counts, platelet volumes and reticulated platelets in patients with ITP: evidence for significant platelet count inaccuracies with conventional instrument methods. Int J Lab Hematol. 2009;31:199–206.
32. Landolfi R, Ciabattoni G, Patrignani P, Castellana MA, Pogliani E, Bizzi B, Patrono C. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin- suppressible platelet activation in vivo. Blood. 1992;80:1965–71.
33. Arellano RE, Alvaréz LA, Reverter JC, Vilamor N, Jou JM, Cervantes F. Automated assessment of the neutrophil and platelet activation status in patients with essential thrombocythemia. Platelets. 2012;23:336–43.
34. Panova NM, Marchetti M, Buoro S, Russo L, Leuzzi A, Finazzi G, Rambaldi A, Ottomano C, Ten CH, Falanga A. JAK2 V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood. 2011;118:2599–601.
35. Thompson CB, Jakubowski JA, Quinn PG, Deykin D, Valeri CR. Platelet size and age determine platelet function independently. Blood. 1984;63:1372–5.
36. Bessman JD, Williams LJ, Gilmer PR Jr. Mean platelet volume. The inverse relation of platelet size and count in normal subjects, and an artifact of other particles. Am J Clin Pathol. 1981;76:289–93.
37. Dahabreh IJ, Zoi K, Giannouli S, Zoi C, Loukopoulos D, Vougarelis M. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res. 2009;33:67–73.
38. Hobbs CM, Manning H, Bennett C, Vasquez L, Severin S, Brain L, Mazharian A, Guerrero JA, Li J, Soranzo N, Green AR, Watson SP, Ghevaer C. JAK2 V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. Blood. 2013;122:3787–97.
39. Martin J. The relationship between megakaryocyte ploidy and platelet volume. Blood Cells. 1989;15:108–21.